Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

XL-184+Abiraterone in Post-Chemo CRPC

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Christopher Sweeney, MBBS, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01574937
First received: April 8, 2012
Last updated: September 12, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: January 2017
  Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)